Vitamin D and Breast Cancer: Do We Really Need to Wait for Perfect Evidence?
Vitamin D has become one of those strange topics in medicine where the conversation can quickly become polarized.
On one side, you’ll hear claims that nearly everyone should be taking large amounts of vitamin D and that higher vitamin D levels can prevent everything from autoimmune disease to cancer.
On the other side, you’ll hear physicians say that vitamin D supplementation has little proven benefit beyond preventing severe deficiency and maintaining bone health.
I don’t think either extreme is particularly useful.
There is, however, some fascinating research on vitamin D that deserves considerably more attention—especially when we think about preventive medicine and how we make decisions when the evidence isn’t perfect.
The Breast Cancer Study That Got My Attention
A 2018 study published in PLOS ONE pooled data from two randomized trials and a prospective cohort, involving more than 5,000 women.
Researchers examined breast cancer incidence according to women’s measured serum 25-hydroxyvitamin D levels.
The results were striking.
Women with vitamin D levels of 60 ng/mL or higher had an approximately 80% lower risk of breast cancer compared with women whose levels were below 20 ng/mL, after adjustment for age, BMI, smoking, calcium supplementation and study cohort.
There was also evidence of a dose-response relationship: breast cancer risk decreased as vitamin D levels increased.
Does that mean maintaining a vitamin D level of 60 ng/mL prevents breast cancer?
No.
The study cannot establish that.
But an 80% association with a disease as consequential as breast cancer certainly deserves our attention.
And it raises a larger question about how we practice preventive medicine.
What If Vitamin D Were a Drug?
Imagine that researchers discovered a new pharmaceutical and found that people exposed to it had an 80% lower incidence of breast cancer.
Would we immediately declare that the drug prevents breast cancer?
Of course not.
We would want randomized controlled trials.
But would the medical community shrug and say, “There’s no proven benefit”?
Almost certainly not.
An association that large would generate enormous interest and substantial investment in additional research.
And this is where vitamin D presents an interesting problem.
Vitamin D isn’t a proprietary medication. It is inexpensive, widely available and already essential to normal human physiology.
There isn’t necessarily the same financial incentive to conduct an enormous, decade-long trial in which thousands of women are individually supplemented and monitored to maintain a particular vitamin D level.
So the definitive study everyone would like to see may never happen.
Why Randomized Trials Still Matter
There is an important reason researchers don’t simply accept the 80% number at face value.
Observational relationships can be misleading.
Women with higher vitamin D levels may exercise more, spend more time outside, have different body composition, eat differently or engage in other health behaviors that influence breast cancer risk.
Researchers can statistically adjust for many of these factors, but they can never eliminate every possible confounder.
Randomization helps solve that problem.
But there is another problem that receives considerably less attention:
Many vitamin D trials haven’t actually tested the hypothesis that vitamin D advocates are proposing.
Giving everyone 2,000 IU of vitamin D per day is not the same experiment as getting everyone to an optimal serum vitamin D concentration.
Dose Is Not the Same Thing as Blood Level
People respond very differently to vitamin D supplementation.
Two people can take exactly the same dose and end up with very different blood levels.
Body weight, absorption, sun exposure, genetics, baseline vitamin D status and other factors influence the response.
So imagine a study gives thousands of people 2,000 IU per day and concludes that vitamin D supplementation doesn’t significantly reduce a particular disease.
That’s useful information.
But it answers this question:
Does giving this population 2,000 IU per day prevent this disease?
It does not necessarily answer:
Would maintaining a serum vitamin D level of 40, 50 or 60 ng/mL change disease risk?
Those are different questions.
An ideal trial would measure participants’ baseline vitamin D levels, supplement them individually, repeatedly test them and adjust their doses until the intervention group maintained a predefined serum concentration.
That is much more complicated—and much more expensive—than simply handing everyone the same pill.
What Does Mainstream Medicine Recommend?
Interestingly, current recommendations have actually become more conservative.
The Endocrine Society’s 2024 guideline recommends against routine vitamin D testing in otherwise healthy adults and generally recommends that healthy adults under 75 consume the standard recommended dietary intake rather than routinely supplementing with higher doses.
Their reasoning is straightforward: clinical trials have not established specific 25-hydroxyvitamin D concentrations that reliably improve particular health outcomes.
That’s an evidence-based position.
But evidence-based medicine still requires judgment.
“Clinical trials haven’t established that this improves outcomes” is not the same statement as:
“We know there is no benefit.”
Those two statements are frequently treated as interchangeable when they are not.
The Cost of Waiting Matters Too
Medicine appropriately spends a great deal of time thinking about the potential harm of an intervention.
We should.
But preventive medicine also requires thinking about the potential harm of not intervening.
Suppose maintaining a vitamin D level around 40–60 ng/mL ultimately turns out to modestly reduce the risk of certain cancers, autoimmune diseases or other chronic illnesses.
If we wait 20 years for definitive trials before acting, millions of people will have lived through those 20 years.
That doesn’t mean we should recommend unproven treatments indiscriminately.
It means the threshold for acting should depend partly on the risk of the intervention.
A medication with significant potential toxicity requires an extremely high evidentiary bar.
A relatively inexpensive intervention with a wide therapeutic window presents a different risk-benefit calculation.
Vitamin D isn’t completely harmless. Excessive supplementation can cause hypercalcemia and kidney problems, and certain medical conditions can make people particularly susceptible.
But that is also why testing can be useful when higher-dose supplementation is being considered.
Rather than guessing, clinicians can measure serum 25-hydroxyvitamin D, supplement appropriately and recheck it.
“Adequate” and “Optimal” Are Different Questions
Another important distinction gets lost in these conversations.
A vitamin D level sufficient to prevent rickets or osteomalacia may not necessarily be the vitamin D level associated with optimal immune, metabolic or cancer-related outcomes.
Nutrition recommendations have historically been designed largely around preventing deficiency diseases.
Preventing deficiency and optimizing physiology are not automatically the same goal.
At the same time, we should be careful not to assume that higher is always better. Biology rarely works that way.
The real scientific question isn’t:
“Should everyone take massive amounts of vitamin D?”
It’s:
“Is there a range of vitamin D status above the threshold for overt deficiency that provides additional health benefits?”
That question remains open.
Where I Land
I don’t think the existing evidence allows us to tell women that maintaining a vitamin D level of 60 ng/mL will reduce their breast cancer risk by 80%.
That would overstate what the research demonstrates.
But I also don’t think an association of this magnitude should be casually dismissed simply because it hasn’t yet been reproduced in the perfect randomized controlled trial.
When an intervention is relatively inexpensive, physiologically plausible and reasonably safe when appropriately monitored, waiting indefinitely for perfect evidence carries its own opportunity cost.
For me, that is what personalized preventive medicine is about.
Measure.
Assess the individual.
Discuss what we know and what we don’t know.
Consider both potential benefit and potential harm.
Intervene thoughtfully.
And then measure again.
We don’t need to pretend the science is more certain than it is.
But we also don’t need perfect certainty before we’re allowed to use clinical judgment.
Ready to Take Control of Your Preventative Health?
Don’t navigate optimal nutrient levels alone. Whether you’re interested in comprehensive lab testing or optimizing your vitamin D levels safely, personalized guidance makes all the difference. Schedule Your Consultation Today or call our San Rafael clinic at (415) 630-5322 to speak with Dr. Amy Shouse Filippelli.
